Topic: Research News

Scientists have developed a new way to study viral proteins that covers their outer surfaces. This helps them understand how antibodies recognize and stop viruses, which can lead to better vaccine design.

Viruses are very good at entering human cells because of special proteins on their surface. These proteins are important targets in vaccine development. To study these proteins, scientists usually create simplified versions in the lab. However, these simplified versions often leave out important parts that normally sit within the virus's outer membrane. As a result, they do not always behave the same way as they would in a real infection, making it harder to understand how antibodies truly recognize and stop viruses.

Researchers at Scripps Research, working with IAVI and other collaborators, have now developed a new platform that allows these viral proteins to be studied in a much more natural form. Their method uses nanodisc technology, which places the proteins into tiny particles made of lipids. This setup mimics the virus's outer membrane, helping preserve the proteins' natural structure and behavior.

The study tested this platform using proteins from HIV and Ebola. These viruses have long posed challenges for vaccine development because their surface proteins are especially difficult for the immune system to target. The researchers believe the same method could also be applied to other viruses with similar membrane-bound proteins, including influenza and SARS-CoV-2.

Implications

Scientists have developed a new way to study viral proteins that covers their outer surfaces. This helps them understand how antibodies recognize and stop viruses, which can lead to better vaccine design.